NEJM on X: "Nivolumab increases median overall survival by 5.4 months in adv renal cell cancer. #ECC2015 http://t.co/9DSZcnbnAs http://t.co/22qcFuEfzN" / X
Metastasectomy and Targeted Therapy for Patients With Spinal Metastases of Renal Cell Carcinoma | International Journal of Spine Surgery
Frontiers | Treatment and survival analysis for 40-year SEER data on upper esophageal cancer
VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer | 2 Minute Medicine
Median overall survival of the patients following all o | Open-i
Kaplan-Meier curves for overall survival. The median overall survival... | Download Scientific Diagram
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
Biology | Free Full-Text | Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
MARGENZA® Clinical Results
Overall survival curve. Median overall survival time was 8.2 months.... | Download Scientific Diagram
Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram
PADCEV® (enfortumab vedotin-ejfv) Efficacy in Patients with la/mUC
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Efficacy Results | ONIVYDE® (irinotecan liposome injection) | HCP | Onivyde
Kaplan–Meier survival curves. (A) Median overall survival was... | Download Scientific Diagram
Cancers | Free Full-Text | Identification of Predictive Factors for Overall Survival and Response during Hypomethylating Treatment in Very Elderly (≥75 Years) Acute Myeloid Leukemia Patients: A Multicenter Real-Life Experience
Survival (time to event) data: median survival times | The BMJ
Prognostic Factors for Gastric Cancer Patients With One Stage IV Factor who Underwent Conversion Surgery | Anticancer Research
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma | NEJM
Kaplan-Meier survival analysis
Efficacy Data | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
estimation - Estimating median survival times from Kaplan-Meier plot inspection - Cross Validated
Median Survival Time - an overview | ScienceDirect Topics
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
GraphPad Prism 10 Statistics Guide - Determining the median followup time
